Judy E. Garber
A leading authority on inherited cancer risk and how BRCA carriers should be treated and screened.
Directs cancer genetics and prevention at Dana-Farber; contributed to the TBCRC neoadjuvant cisplatin trials in BRCA-associated breast cancer and to OlympiA.
| Title | Journal | Year |
|---|---|---|
| Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer | New England Journal of Medicine | 2021 |
Pages like this
not linked directly; found by shared links- PersonSusan M. Domchek
Shares Angelina Jolie, OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing.
- PairingGermline BRCA test → adjuvant PARP inhibitor
Shares OlympiA, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer (TNBC).
- IdeaPopulation germline screening for hereditary cancer genes with cascade testing
Shares Chemoprevention & risk-reducing surgery, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Ovarian cancer.
- InstitutionUniversity of Malaya Medical Centre
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- TechnologyRisk-reducing and opportunistic salpingectomy
Shares Angelina Jolie, Chemoprevention & risk-reducing surgery, BRCA1 / BRCA2 (HRD), Ovarian cancer.
- PersonCharles E. Geyer Jr.
Shares OlympiA, OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).
- PersonAndrew Tutt
Shares OlympiA, OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).
- TermGermline BRCA mutation (gBRCA)
Shares OlympiA, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Ovarian cancer.